deltatrials
Completed PHASE3 INTERVENTIONAL 3-arm NCT04617483

Study of the Commercial Scale SARS-CoV-2 Vaccine Against the Pilot Scale Among Adults, and Bridging Study of the Immunogenicity in Elderly Against That in Adults

A Randomized, Double-Blinded Clinical Trial, to Evaluate the Non-inferiority of the Commercial Scale Inactivated SARS-CoV-2 Vaccine Against That of the Pilot Scale Among Adults Aged 26-45 Years, and the Open-labelled, Bridging Non-inferiority of the Vaccine Induced Immunogenicity in Elderly Against That in Adults

Sponsor: Sinovac Research and Development Co., Ltd.

Conditions Covid19
Interventions Two doses of commercial scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14 Two doses of pilot scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14 Two doses of pilot scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14 in elderly
Updated 5 times since 2020 Last updated: Jul 26, 2021 Started: Oct 31, 2020 Primary completion: Nov 28, 2020 Completion: May 31, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Covid19 and is currently completed. Sinovac Research and Development Co., Ltd. leads this study, which shows 5 recorded versions since 2020 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshotRecruiting~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshotRecruiting~Sep 2021 – ~Jul 2024 · 34 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 24 months · monthly snapshotCompleted

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Sep 2021 — Jul 2024 [monthly]

    Completed PHASE3

    Status: Recruiting → Completed

  4. Jan 2021 — Sep 2021 [monthly]

    Recruiting PHASE3

  5. Dec 2020 — Jan 2021 [monthly]

    Recruiting PHASE3

    First recorded

Oct 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Sinovac Research and Development Co., Ltd.
Data source: Sinovac Biotech Co., Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations